EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

doi:10.1016/j.ejca.2011.12.021

journal article Mar 01, 2012

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

European Journal of Cancer Vol. 48 No. 5 pp. 599-641 · Elsevier BV

View at Publisher Save 10.1016/j.ejca.2011.12.021

Topics

No keywords indexed for this article. Browse by subject →

References

360

[1]

Bruix "EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona–2000 EASL conference. European Association for the Study of the Liver" J Hepatol (2001) 10.1016/s0168-8278(01)00130-1

[2]

National Cancer Institute. PDQ® Levels of Evidence for Adult and Pediatric Cancer Treatment Studies. Bethesda, MD: National Cancer Institute. Date last modified 26/August/2010. Available from: http://cancer.gov/cancertopics/pdq/levels-evidence-adult-treatment/healthprofessional/ [accessed March 1st, 2011].

[3]

Parkin "Global cancer statistics, 2002" CA Cancer J Clin (2005) 10.3322/canjclin.55.2.74

[4]

IARC. Available from: http://www–dep.iarc.fr: [accessed November 1st, 2011].

[5]

El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–750. 10.1056/nejm199903113401001

[6]

Tanaka "Declining incidence of hepatocellular carcinoma in Osaka, Japan from 1990 to 2003" Ann Intern Med (2008) 10.7326/0003-4819-148-11-200806030-00004

[7]

Bosetti "Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004" Hepatology (2008) 10.1002/hep.22312

[8]

Jemal "Cancer Statistics, 2008" CA Cancer J Clin (2008) 10.3322/ca.2007.0010

[9]

Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study

Mei-Hwei Chang, San-Lin You, Chien-Jen Chen et al.

JNCI: Journal of the National Cancer Institute 2009 10.1093/jnci/djp288

[10]

Sangiovanni "The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients" Hepatology (2006) 10.1002/hep.21176

[11]

Ioannou "Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis" Clin Gastroenterol Hepatol (2007) 10.1016/j.cgh.2007.02.039

[12]

Lok "Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease" Gastroenterology (2009) 10.1053/j.gastro.2008.09.014

[13]

Ripoll "Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis" J Hepatol (2009) 10.1016/j.jhep.2009.01.014

[14]

Masuzaki "Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography" Hepatology (2009) 10.1002/hep.22870

[15]

Jung "Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)" Hepatology (2011) 10.1002/hep.24121

[16]

Lok "Prevention of hepatitis B virus-related hepatocellular carcinoma" Gastroenterology (2004) 10.1053/j.gastro.2004.09.045

[17]

Yang "Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma" N Engl J Med (2002) 10.1056/nejmoa013215

[18]

Chen "REVEAL–HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level" JAMA (2006) 10.1001/jama.295.1.65

[19]

Yu "Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men" J Natl Cancer Inst (2005) 10.1093/jnci/dji043

[20]

Iloeje "Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer–In HBV (the REVEAL–HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load" Gastroenterology (2006) 10.1053/j.gastro.2005.11.016

[21]

Raimondi "Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis" J Hepatol (2009) 10.1016/j.jhep.2009.01.019

[22]

Hsu "Mutational hotspot in the p53 gene in human hepatocellular carcinomas" Nature (1991) 10.1038/350427a0

[23]

Deugnier "Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases" Gastroenterology (1993) 10.1016/0016-5085(93)90856-8

[24]

Perlmutter "Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency" Pediatr Res (2006) 10.1203/01.pdr.0000228350.61496.90

[25]

Polio "Hepatocellular carcinoma in Wilson’s disease. Case report and review of the literature" J Clin Gastroenterol (1989) 10.1097/00004836-198904000-00022

[26]

El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case–control study among United States Veterans. Am J Gastroenterol 2001;96:2462–67. 10.1111/j.1572-0241.2001.04054.x

[27]

Marrero "Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma" J Hepatol (2005) 10.1016/j.jhep.2004.10.005

[28]

Trichopoulos "Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case–control study" J Natl Cancer Inst. (2011) 10.1093/jnci/djr395

[29]

Marcellin "Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption" J Hepatol (2008) 10.1016/j.jhep.2007.09.010

[30]

A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1

Yoshio Miki, Jeff Swensen, Donna Shattuck-Eidens et al.

Science 1994 10.1126/science.7545954

[31]

Marra "Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives" J Natl Cancer Inst (1995) 10.1093/jnci/87.15.1114

[32]

Tanabe "Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis" JAMA (2008) 10.1001/jama.2007.65

[33]

Clifford "Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma" Hepatology (2010) 10.1002/hep.23943

[34]

Hepatitis B vaccines. Weekly epidemiological record of the World Health Organization 2009;84,405–20.

[35]

European Association for the Study of the Liver "EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B" J Hepatol (2009) 10.1016/j.jhep.2008.10.001

[36]

European Association for the Study of the Liver "EASL Clinical Practice Guidelines: Management of hepatitis C virus infection" J Hepatol (2011) 10.1016/j.jhep.2011.02.023

[37]

Niederau "Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B" N Engl J Med (1996) 10.1056/nejm199605303342202

[38]

Yuen "Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy" Hepatology (2001) 10.1053/jhep.2001.27563

[39]

Liaw "Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease" N Engl J Med (2004) 10.1056/nejmoa033364

[40]

Singal "A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus" Clin Gastroenterol Hepatol (2010) 10.1016/j.cgh.2009.11.018

[41]

Nishiguchi "Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis" Lancet (1995) 10.1016/s0140-6736(95)91739-x

[42]

Valla "Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment" Hepatology (1999) 10.1002/hep.510290616

[43]

Lok "HALT-C Trial Group. Maintenance Peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C" Gastroenterology (2011) 10.1053/j.gastro.2010.11.050

[44]

Di Bisceglie "HALT-C Trial Group. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon" Hepatology (2011) 10.1002/hep.24169

[45]

Bruix "EPIC3 Study Group. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C" Gastroenterology (2011) 10.1053/j.gastro.2011.03.010

[46]

Prorok "Epidemiologic approach for cancer screening. Problems in design and analysis of trials" Am J Pediatr Hematol Oncol (1992) 10.1097/00043426-199205000-00005

[47]

El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118–27. 10.1056/nejmra1001683

[48]

Laupacis "How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations" CMAJ (1992)

[49]

Sarasin "Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis" Am J Med (1996) 10.1016/s0002-9343(96)00197-0

[50]

Fattovich "Hepatocellular carcinoma in cirrhosis: incidence and risk factors" Gastroenterology (2004) 10.1053/j.gastro.2004.09.014

Showing 50 of 360 references

Cited By

364

Hepatocellular carcinoma surveillance: An evidence-based approach

Patrick S Harris, Ross M Hansen · 2019

World Journal of Gastroenterology

Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review

Saleh Daher, Muhammad Massarwa · 2017

Journal of Clinical and Translation...

Metrics

364

Citations

360

References

Details

Published: Mar 01, 2012
Vol/Issue: 48(5)
Pages: 599-641
License: View

Cite This Article

(2012). EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. European Journal of Cancer, 48(5), 599-641. https://doi.org/10.1016/j.ejca.2011.12.021

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

You May Also Like